Benjamin A. Nacev, MD Ph.D.
Affiliations: | 2022- | University of Pittsburgh School of Medicine, Pittsburgh, PA, United States |
Area:
Chromatin BiologyWebsite:
https://nacevlab.com/Google:
"https://scholar.google.com/citations?user=dAs6D6YAAAAJ&hl=en&oi=ao"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Jun O. Liu | grad student | University of Pittsburg Medical School | ||
| Jun O. Liu | grad student | 2013 | Johns Hopkins | |
| (Mechanistic studies of clinical drugs with unexplained antiangiogenic activity.) | ||||
| C. David Allis | post-doc | 2017-2022 | Rockefeller | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nacev BA, Dabas Y, Paul MR, et al. (2024) Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiation. Nature Communications. 15: 5155 |
| Bagert JD, Mitchener MM, Patriotis AL, et al. (2021) Oncohistone mutations enhance chromatin remodeling and alter cell fates. Nature Chemical Biology |
| Nacev BA, Jones KB, Intlekofer AM, et al. (2020) The epigenomics of sarcoma. Nature Reviews. Cancer |
| Nacev BA, Feng L, Bagert JD, et al. (2019) The expanding landscape of 'oncohistone' mutations in human cancers. Nature |
| Nacev BA, Tap WD. (2018) TOMAS: revisiting PARP inhibitor combination therapy. The Lancet. Oncology |
| Head SA, Shi WQ, Yang EJ, et al. (2017) Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. Acs Chemical Biology. 12: 174-182 |
| Kshitiz, Afzal J, Suhail Y, et al. (2015) Control of the interface between heterotypic cell populations reveals the mechanism of intercellular transfer of signaling proteins. Integrative Biology : Quantitative Biosciences From Nano to Macro. 7: 364-72 |
| Pandey R, Botros MA, Nacev BA, et al. (2015) Cyclosporin a disrupts notch signaling and vascular lumen maintenance. Plos One. 10: e0119279 |
| Chi P, Qin L, Kelly CM, et al. (2015) A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 33: 10507-10507 |
| Zhang F, Bhat S, Gabelli SB, et al. (2013) Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells Journal of Medicinal Chemistry. 56: 3996-4016 |